Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 8
Submit an article Journal homepage
202
Views
2
CrossRef citations to date
0
Altmetric
Review

Treatment of autism spectrum disorders: neurotransmitter signaling pathways involved in motivation and reward as therapeutic targets

Michael A Walker Bristol-Myers Squibb Co., Medicinal Chemistry, Research and Development, Wallingford, CT, USA +1 203 677 6686; +1 203 677 7702; [email protected]
Pages 949-967 | Published online: 12 Jul 2008

Bibliography

  • Diagnostic and Statistical Manual of Mental Disorders. 4th edition. american psychiatric associate; Washington, DC; 1994
  • International classification of diseases. 10th edition. world health organization, Geneva Switzerland; 1992
  • Ganz ML. The lifetime distribution of the incremental societal costs of autism. Arch Pediatr Adolesc Med 2007;161:343-349
  • Autism Prevalence in the US. Rises to 1 in 150; 2007. Available from: www.autism-society.org/site/News2?page=NewsArticle&id=9289 [Last accessed 12 May 2008]
  • Thornton-Wells TA, Moore JH, Haines JL. Genetics, statistics and human disease: analytical retooling for complexity. Trends Genet 2004;20(12):640-7
  • Veenstra-Vanderweele J, Christian SL, Cook EH Jr. Autism as a paradigmatic complex genetic disorder. Ann Rev Genomics Hum Genet 2004;5:379-405
  • Grant SGN. Systems biology in neuroscience: bridging genes to cognition. Current Opin Neurobiol 2003;13:577-82
  • Baron-Cohen S, Ring HA, Bullmore ET, et al. The amygdala theory of autism. Neurosci Biobehav Rev 2000;24(3):355-64
  • Insel TR. Is social attachment an addictive disorder? Physiol Behav 2003;79(3):351-7
  • Kovacs GL, Sarnyai Z, Szabo G. Oxytocin and addiction: a review. Psychoneuroendocrinology 1998;23(8):945-62
  • Hammock EAD, Young LJ. Oxytocin, vasopressin and pair bonding: implications for autism. Philosoph Trans Royal Soc B Biol Sci 2006;361(1476):2187-98
  • Lim MM, Young LJ. Neuropeptidergic regulation of affiliative behavior and social bonding in animals. Hormones Behav 2006;50(4):506-17
  • Young LJ, Wang Z. The neurobiology of pair bonding. Nature Neurosci 2004;7(10):1048-54
  • Winslow JT, Hastings N, Carter CS, et al. A role for central vasopressin in pair bonding in monogamous prairie voles. Nature 1993;365(6446):545-8
  • Le Moal M, Dantzer R, Michaud B, Koob GF. Centrally injected arginine vasopressin (AVP) facilitates social memory in rats. Neurosci Lett 1987;77(3):353-9
  • Landgraf R, Gerstberger R, Montkowski A, et al. V1 vasopressin receptor antisense oligodeoxynucleotide into septum reduces vasopressin binding, social discrimination abilities, and anxiety-related behavior in rats. J Neurosci 1995;15(6):4250-8
  • Everts HGJ, Koolhaas JM. Lateral septal vasopressin in rats: role in social and object recognition? Brain Res 1997;760(1-2):1-7
  • Levy F, Kendrick KM, Goode JA, et al. Oxytocin and vasopressin release in the olfactory bulb of parturient ewes: changes with maternal experience and effects on acetylcholine, γ-aminobutyric acid, glutamate and noradrenaline release. Brain Res 1995;669(2):197-206
  • Ferguson JN, Aldag J, Matthew I, et al. Oxytocin in the medial amygdala is essential for social recognition in the mouse. 2001;21(20):8278-85
  • Takayanagi Y, Yoshida M, Bielsky IF, et al. Pervasive social deficits, but normal parturition, in oxytocin receptor-deficient mice. 2005;102(44):16096-101
  • Bielsky IF, Hu S-B, Re X, et al. The V1a vasopressin receptor is necessary and sufficient for normal social recognition: a gene replacement study. Neuron 2005;47(4):503-13
  • Bielsky IF, Young LJ. Oxytocin, vasopressin, and social recognition in mammals. Peptides 2004;25(9)1565-74
  • Jin D, Liu H-X, Hirai H, et al. CD38 is critical for social behaviour by regulating oxytocin secretion. Nature 2007;446(7131):41-5
  • Modahl C, Green LA, Fein D, et al. Plasma oxytocin levels in autistic children. Biol Psychiatry 1998;43(4):270-7
  • Green L-A, Fein D, Modahl C, et al. Oxytocin and autistic disorder: alterations in peptide forms. Biol Psychiatry 2001;50(8):609-13
  • Wu S, Jia M, Ruan Y, et al. Positive association of the oxytocin receptor gene (OXTR) with autism in the Chinese Han population. Biol Psychiatry 2005;58(1):74-7
  • Inoue T, Kimura T, Azuma C, et al. Structural organization of the human oxytocin receptor gene. J Biol Chem 1994;269(51):32451-6
  • Baron-Cohen S, Wheelwright S, Hill J, et al. The “reading the mind in the eyes” test, revised version: a study with normal adults, and adults with Asperger syndrome or high-functioning autism. J Child Psychol Psychiatry Allied Discp 2001;42(2):241-51
  • Domes G, Heinrichs M, Michel A, et al. Oxytocin improves “mind reading” in humans. Biol Psychiatry 2007;61(6):731-3
  • Kosfeld M, Heinrichs M, Zak PJ, Fischbacher U, Fehr E. Oxytocin increases trust in humans. Nature 2005;435(7042):673-6
  • Zak, PJ, Kurzban R, Matzner WT. Oxytocin is associated with human trustworthiness. Horm Behav 2005;48(5):522-7
  • Stein MB, Goldin PR, Sareen J, et al. Increased amygdala activation to angry and contemptuous faces in generalized social phobias. Arch Gen Psychiatry 59(11):1027-34
  • Kirsch P, Esslinger C, Chen Q, et al. Oxytocin modulates neural circuitry for social cognition and fear in humans. J Neurosci 2005;25(49):11489-93
  • Meyer-Lindenberg A, Hariri AR, Munoz KE, et al. Neural correlates of genetically abnormal social cognition in Williams syndrome. Nat Neurosci 2005;8(8):991-3
  • Hollander E, Novotny S, Hanratty M, et al. Oxytocin infusion reduces repetitive behaviours in adults with autistic and Asperger disorder. Neuropsychopharmacol 2003;28(1):193-8
  • Hollander E, Bartz J, Chaplin W, et al. Oxytocin increases retention of social cognition in autism. Biol Psychiatry 2006;61(4):498-503
  • Kim S-J, Young LJ, Gonen d, et al. Transmission disequilibrium testing of arginine vasopressin receptor 1A (AVPR1A) polymorphisms in autism. Mol Psychiatry 2002;7(5):503-7
  • Wassink TH, Piven J, Vieland VJ, et al. Examination of AVPR1a as an autism susceptibility gene. Mol Psychaitr 2004;9(10):968-72
  • Yirmiya N, Rosenberg, C, Levi S, et al. Association between the arginine vasopressin 1a receptor (AVPR1a) gene and autism in a family-based study: mediation by socialization skills. Mol Psychiatry 2006;11(5):488-94
  • Ring RH, Malberg JE, Potestio L, et al. Anxiolytic-like activity of oxytocin in male mice: behavioral and autonomic evidence, therapeutic implications. Psychopharmacology 2006;185(2):218-25
  • De Groot AN, Vree TB, Hekster YA, et al. Bioavailability and pharmacokinetics of sublingual oxytocin in male volunteers. J Pharm Pharmacol 1995;47(7):571-5
  • Meraldi JP, Hruby VJ, Brewster AI. Relative conformational rigidity in oxytocin and [1-penicillamine]-oxytocin: a proposal for the relationship of conformational flexibility to peptide hormone agonism and antagonism. Proc Natl Acad Sci USA 1977;74(4):1373-7
  • Yuan Z-Q, Blomberg D, Sethson I, et al. Synthesis and pharmacological evaluation of an analogue of the peptide hormone oxytocin that contains a mimetic of an inverse γ-turn. J Med Chem 2002;45(12):2512-9
  • Hruby VJ, Chow MS, Smith DD. Conformational and structural considerations in oxytocin-receptor binding and biological activity. Ann Rev Pharmacol Toxicol 1990;30:501-34
  • Wittelsberger A, Patiny L, Slaninova J, et al. Introduction of a cis-prolyl mimic in position 7 of the peptide hormone oxytocin does not result in antagonistic activity. J Med Chem 2005;48(21):6553-62
  • Hruby VJ. Designing peptide receptor agonists and antagonists. Nat Rev Drug Disc 2002;1(11):847-58
  • Engstrøm T, Barth T, Melin P, Vilhardt H. Oxytocin receptor binding and uterotonic activity of carbetocin and its metabolites following enzymatic degradation. Eur J Pharmacol 1998;355(2-3):203-10
  • Stymiest JL, Mitchell BF, Wong S, Vederas JC. Synthesis of biologically active dicarba analogues of the peptide hormone oxytocin using ring-closing metathesis. Org Lett 2003;5(1):47-9
  • Keller O, Rudiger J. Synthesis of (1,6-α,α′-diaminosuberic acid) oxytocin (dicarba-oxytocin). Helv Chim Acta 1974;57(5):1253-9
  • Walter R, Yamanaka T, Sakakibara S. Neurohypophyseal hormone analog with selective oxytocin-like activities and resistance to enzymatic inactivation. Approach to the design of peptide drugs. Proc Natl Acad Sci USA 1974;71(5):1901-5
  • Evans BE, Leighton JL, Rittle KE, et al. Orally active, nonpeptide oxytocin antagonists. J Med Chem 1992;35(21):3919-27
  • Bell IM, Erb JM, Freidenger RM, et al. Development of orally active oxytocin antagonists, Studies on 1-(1-{4-[20methyl-1-oxidopyridin-3-ylmethyl] piperidin-4-yloxy}-2-methoxybenzoly)piperidin-4-yl)-1,4-dihydrobenz[d] [1,3]oxazin-2-one (L-372,662) and related pyridines. J Med Chem 1998;41(12):2146-63
  • Pitt RW, Batt AR, Haigh RM, et al. Non-peptide oxytocin agonists. Bioorg Med Chem Lett 2004;14(17):4585-9
  • Ashworth DM, Batt AR, Baxter AJ, et al. Nonpeptide oxytocin agonists. Drugs Future 2006;31(4):345-53
  • Schroer RJ, Phelan MC, Michaelis RC, et al. Autism and maternally derived aberrations of chromosome 15q. Am J Med Genet 1998;76(4):327-36
  • Blatt GJ. GABAergic cerebellar system in autism: a neuropathological and developmental perspective. Int Rev Neurobiol 2005;71:167-78
  • Rivto ER, Freeman BJ, Scheibel AB, et al. Lower Purkinje cell counts in the cerebella of four autistic subjects: initial findings of the UCLA-NSCA autopsy research report. Am J Psychiatry 1986;143(7):862-6
  • Mccauley JL, Olson LM, Delahanty R, et al. A linkage disequilibrium map of the 1-Mb 15q12 GABAA receptor subunit cluster and association to autism. Am J Med Genet Part B Neuropsych Genetics 2004;131(1):51-9
  • Bass MP, Menold MM, Wolpert M, et al. Genetic studies in autistic disorder and chromosome 15. Neurogenetics 2000;2(4):219-26
  • Chagnon YC. Shared chromosomal susceptibility regions between autism and other mental disorders. Int Rev Neurobiol 2005;71:419-43
  • Takayama C. GABAergic signalling in the developing cerebellum. Int Rev Neurobiol 2005;71:63-94
  • Ben-Ari Y. Excitatory actions of GABA during development: the nature of the nurture. Nature Rev Neurosci 2002;3(9):728-39
  • Laviolette SR, Gallegos RA, Henriksen SJ, Van Der Kooy D. Opiate state controls bi-directional reward signalling via GABAA receptors in the ventral tegmental area. Nature Neurosci 2004;7(2):160-9
  • Ikemoto S. The supramammillary nucleus mediates primary reinforcement via GABAA receptors. Neuropsychopharmacology 2005;30:1088-95
  • Johnson BA. Recent advances in the development of treatments for alcohol and cocaine dependence. CNS Drugs 2005;19(10):873-96
  • Solis-Anez E, Delgado-Luengo W, Borjas-Fuentes L, et al. Molecular analysis of the GABRB3 gene in autistic patients: an exploratory study. Invest Clin 2007;48(2):225-42
  • Cook EH Jr, Courchesne RY, Cox NJ, et al. Linkage-disequilibrium mapping of autistic disorder, with 15q11-13 markers. Am J Hum Genet 1998;62(5):1077-83
  • Buxbaum JD, Silverman JM, Smith CJ, et al. Association between a GABRB3 polymorphism and autism. Mol Psychiatry 2002;7(3):311-6
  • Menold MM, Shao Y, Wolpert CM, et al. Association analysis of chromosome 15 GABAA receptor subunit genes in autistic disorder. J Neurogenet 2001;15(3-4):245-59
  • Shao Y, Cuccaro ML, Hauser ER, et al. Fine mapping of autistic disorder to chromosome 15q11-q13 by use of phenotypic subtypes. Am J Hum Genet 2003;72(3):539-48
  • Guptill JT, Booker AB, Gibbs TT, et al. [3H]-Flunitrazepam-labeled benzodiazepine binding sites in the hippocampal formation in autism: a multiple concentration autoradiographic study. J Autism Dev Disord 2007;37(5):911-20
  • Curran S, Powell J, Neale BM, et al. An association analysis of candidate genes on chromosome 15 q11-13 and autism spectrum disorder. Mol Psychiatry 2006;11(8):709-13
  • Fatemi SH, Halt AR, Stary JM, et al. Glutamic acid decarboxylase 65 and 67 kDa proteins are reduced in autistic parietal and cerebellar cortices. Biol Psychiatry 2002;52(8):805-10
  • Yip J, Soghomonian J-J, Blatt GJ. Decreased GAD67 mRNA levels in cerebellar Purkinje cells in autism: pathological implications. Acta Neuropathol 2007;113(5):559-68
  • Moreno-Fuenmayor H, Borjas L, Arrieta A, et al. Plasma excitatory amino acids in autism. Invest Clin 1996;37(2):113-28
  • Aldred S, Moore KM, Fitzgerald M, Waring RH. Plasma amino acid levels in children with autism and their families. J Autism Dev Disord 2003;33(1):93-7
  • Shinohe A, Hashimoto K, Nakamura K, et al. Increased levels of glutamate in adult patients with autism. Prog Neuropsychopharmacol Biol Psychiatry 2006;30:1472-7
  • Page LA, Daly E, Schmitz N, et al. In vivo 1H-magnetic resonance spectroscopy study of amygdala-hippocampal and parietal regions in autism. Am J Psychiatry 2006;163:2189-92
  • Coulter DA. Antiepileptic drug cellular mechanisms of action: where does lamotrigine fit in? J Child Neurol 1997;12(Suppl 1):S2-9
  • Belsito KM, Law PA, Kirk KS, et al. Lamotrigine therapy for autistic disorder: A randomized, double-blind, placebo-controlled trial. J Autism Dev Disord 2001;32(2):175-81
  • King BH, Wright DM, Handen BL, et al. Double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 2001;40(6):658-65
  • Woodward C, Groden J, Goodwin M, Bodfish J. A placebo double-blind pilot study of dextromethorphan for problematic behaviours in children with autism. Autism 2007;11(1):29-41
  • Schmitz C, Van Kooten IA, Hof PR, et al. Steinbusch HW, Autism: neuropathology, alterations of the GABAergic system, and animal models. Int Rev Neurobiol 2005;71:1-26
  • Delorey TM, Sahbaie P, Hashemi E, et al. GARB3 gene deficient mice exhibit impaired social and exploratory behaviours, deficits in non-selective attention and hypoplasia of cebrellar vermal lobules: A potential model of autism spectrum disorder. Behav Brain Res 2008;187(2):207-20
  • Chebib M, Johnston GAR. GABA-activated ligand gated ion channels: medicinal chemistry and molecular biology. J Med Chem 2000;43(8):1427-47
  • Whiting PJ. The GABAA receptor gene family: New opportunities for drug development. Curr Opin Drug Discov Devel 2003;6(5):648-57
  • Sieghart W. GABAA receptors as targets for different classes of drugs. Drugs Future 2006;31(8):685-94
  • Marrosu G, Rachel MG, Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol 1987;2(3):355-61
  • Mazzone L, Ruta L. Topiramate in children with autistic spectrum disorders. Brain Dev 2006;28(10):688
  • Fisman S, Steele M. Use of risperidone in pervasive developmental disorders: a case study. J Child Adolesc Psychopharmacol 1996;6(3):177-90
  • Nieoullon A. Dopamine and the regulation of cognition and attention. Prog Neurobiol 2002;571:1-31
  • Salgado-Pineda P, Delaveau P, Blin O, Nieoullon A. Dopaminergic contribution to the regulation of emotional perception. Clin Neuropharmacol 2005;28(5):228-37
  • Lauritsen MB, Børglum AD, Betancur C, et al. Investigation of two variants in the DOPA decarboxylase gene in patients with autism. Am J Med Genet 2002;114(4):466-70
  • Anderson GM, Freedman DX, Cohen DJ, et al. Whole blood serotonin in autistic and normal subjects. J Child Psychol Psychiatry 1987;28(6):885-900
  • Corbett R, Hartman H, Kerman LL, et al. effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol Biochem Behav 1993;45(1):9-17
  • Takahashi H, Yahata N, Koeda M, et al. Effects of dopaminergic and serotonergic manipulation on emotional processing: a pharmacological fMRI study. Neuroimage 2005;27(4):991-1001
  • Delaveau P, Salgado-Pineda P, Wicker B, et al. Effect of levodopa on healthy volunteers' facial emotion perception: an fMRI study. Clin Neuropharmacol 2005;28(6):255-61
  • Hariri AR, Mattay VS, Tessitore A, et al. Dextroamphetamine modulates the response of the human amygdala. Neuropsychopharmacology 2002;27(6):1036-40
  • Kee KS, Kern RS, Marshall Jr BD, Green Mf. Risperidone versus haloperidol for perception of emotion in treatment-resistant schizophrenia: preliminary findings. Schizophr Res 1998;31(2-3):159-65
  • Gillberg C. Svennerholm L CSF monoamines in autistic syndromes and other pervasive developmental disorders of early childhood. Br J Psychiatry 1987;151:89-94
  • Martineau J, Hérault J, Petit E, et al. Catecholaminergic metabolism and autism. Dev Med Child Neurol 1994;36(6):688-97
  • Eto I, Bandy MD, Butterworth CE Jr. Plasma and urinary levels of biopterin, neopterin, and related pterins and plasma levels of folate in infantile autism. J Autism Dev Disord 1992;22(2):295-308
  • Tani Y, Fernell E, Watanabe Y, et al. Decrease in 6R-5,6,7,8-tetrahydrobiopterin content in cerebrospinal fluid of autistic patients. Neurosci Lett 1994;181(1-2):169-72
  • Komori H, Matsuishi T, Yamada S, et al. Cerebrospinal fluid biopterin and biogenic amine metabolites during oral R-THBP therapy for infantile autism. J Autism Dev Disord 1995;25(2):183-93
  • Fernell E, Watanabe Y, Adolfsson I, et al. Possible effects of tetrahydrobiopterin treatment in six children with autism-clinical and positron emission tomography data: a pilot study. Dev Med Child Neurol 1997;39(5):313-8
  • Ernst M, Zametkin AJ, Matochik JA, et al. Low medial prefrontal dopaminergic activity in autistic children. Lancet 1997;350(9078):638
  • Posey DJ, Aman MG, McCracken JT, et al. Positive effects of methylphenidate on inattention and hyperactivity in pervasive developmental disorders: an analysis of secondary measures. Biol Psychiatry 2007;61(4):538-44
  • Posey DJ, Aman MG, Arnold LE, et al. Randomized, controlled, crossover trial of methylphenidate in pervasive developmental disorders with hyperactivity. Arch Gen Psychiatry 2005;62(11):1266-74
  • Handen BL, Johnson CR. Lubetsky M Efficacy of methylphenidate among children with autism and symptoms of attention-deficit hyperactivity disorder. J Autism Dev Disord 2000;30(3):245-55
  • Quintana H, Birmaher B, Stedge D, et al. Use of methylphenidate in the treatment of children with autistic disorder. J Autism Dev Disord 1995;25(3):283-94
  • Niederhofer H, Damodharan SK, Joji R, Corfield A. Atomoxetine treating patients with autistic disorder. Autism 2006;10(6):646-9
  • Arnold LE, Aman MG, Cook AM, et al. Atomoxetine for hyperactivity in autism spectrum disorders: placebo-controlled crossover pilot trial. J Am Acad Child Adolesc Psychiatry 2006;45(10):1196-205
  • Carlsson A, Carlsson ML. A dopaminergic deficit hypothesis of schizophrenia: the path to discovery. Dialogues Clin Neurosci 2006;8(1):137-42
  • Lieberman JA. Dopamine partial agonists: a new class of antipsychotic. CNS Drugs 2004;14(4):251-67
  • Sonesson C, Lin C-H, Hansson L, et al. Substituted (S)-phenylpiperidines and rigid congeners as preferential dopamine autoreceptor antagonists: synthesis and structure-activity relationships. J Med Chem 1994;37(17):2735-53
  • Natesan S, Svensson KA, Reckless GE, et al. The dopamine stabilizers (S)-(-)-(3-Methanesulfonyl-phenyl)- 1-propyl-piperidine [(-)-OSU6162] and 4-(3-Methanesulfonylphenyl)- 1-propyl-piperidine (ACR16) show high in vivo D2 receptor occupancy, antipsychotic-like efficacy, and low potential for motor side effects in the rat. J Pharmacol Exp Ther 2006;318(2):818-9
  • Albert VR, Lee MR, Bolden AH, et al. Distinct promoters direct neuronal and nonneuronal expression of rat aromatic L-amino acid decarboxylase. Proc Natl Acad Sci USA 1992;89(24):12053-7
  • Vassilacopoulou D, Sideris DC, Vassiliou AG, Fragoulis EG. Identification and characterization of a novel form of the human L-dopa decarboxylase mRNA. Neurochem Res 2004;29(10):1817-23
  • Chang YT, Mues G, Hyland H. Alternative splicing in the coding region of human aromatic L-amino acid decarboxylase mRNA. Neurosci Lett 1996;202(3):157-60
  • O'Malley KL, Harmon S, Moffat M, et al. The human aromatic L-amino acid decarboxylase gene can be alternatively spliced to generate unique protein isoforms. J Neurochem 1995;65(6):2409-16
  • Ichinose H, Sumi-Ichinose C, Ohye T, et al. Tissue specific alternative splicing of the first exon generates two types of mRNAs in human aromatic L-amino acid decarboxylase. Biochemistry 1992;31(46):11546-50
  • Watanabe Y, Hashimoto S, Kakita A, et al. Neonatal impact of leukemia inhibitory factor on neurobehavioral development in rats. Neurosci Res 2004;48(3):345-53
  • Bejerot S, Nylander L. Low prevalence of smoking in patients with autistic spectrum disorders. Psychiatry Res 2003;119(2):177-82
  • Perry EK, Lee MLW, Martin-Ruiz CM, et al. Cholinergic activity in autism: Abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry 2001;158(7):1058-66
  • Lee M, Martin-Ruiz C, Graham A, et al. Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain 2002;125(7):1483-95
  • Ray MA, Graham AJ, Lee M, et al. Neuronal nicotinic receptor subunits in autism: An immunohistochemical investigation in the thalamus. Neurobiol Dis 2005;19(3):366-77
  • Nicolson R, Craven-Thuss B, Smith J. A prospective, open-label trial of galantamine in autistic disorder. J Child Adole Psychopharm 2006;16(5):621-9
  • Chez MG, Aimonovitch M, Buchanan T, et al. Treating autistic spectrum disorders in children: Utility of the cholinesterase inhibitor rivastigmine tartrate. J Child Neurol 2004;19(3):165-9
  • Lin N-H, Gunn DE, Ryther KB, et al. Structure-activity studies on 2-methyl-3-(2(S)-pyrrolidinylmethoxy)pyridine (ABT-089): An orally bioavailable 3-pyridyl ether nicotinic acetylcholine receptor ligand with cognition-enhancing properties. J Med Chem 1997;40(3):385-90
  • Bencherif M, Lovette ME, Fowler KW, et al. RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. J Pharmacol Exp Ther 1996;279(3):1413-21
  • Lippiello PM, Bencherif M, Gray JA, et al. RJR-2403, A nicotinic agonist with CNS selectivity II. In vivo characterization. J Pharmacol Exp Ther 1996;279(3):1422-9
  • AZD3480 (TC-1734) – Cognitive impairment, including Alzheimer's disease and cognitive dysfunction in schizophrenia. Available from: www.targacept.com/wt/page/tc_1734 [Last accessed 12 May 2008]
  • Cohen C, Bergis OE, Galli F, et al. SSR591813, a novel selective and partial (4(2 nicotinic receptor agonist with potential as an aid to smoking cessation. J Pharmacol Exp Ther 2003;306(1):407-20

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.